超声心动图与接受多巴胺激动剂治疗的高催乳素血症患者的监测:英国超声心动图学会、英国心脏瓣膜学会和内分泌学会的联合立场声明
该联合立场声明指出,多巴胺激动剂治疗高催乳素血症导致异常瓣膜形态和功能的证据极为有限,除孤立病例报告外无临床显著瓣膜病变证据。建议开始治疗前行标准经胸超声心动图,每周卡麦角林总剂量≤2 mg者用药5年后复查,无变化可每5年复查,>2 mg者每年复查。
要点
- 开始多巴胺激动剂治疗高催乳素血症前应行标准经胸超声心动图。
- 卡麦角林每周总剂量≤2 mg者用药5年后复查超声心动图。
- 每周总剂量>2 mg者推荐每年复查超声心动图。
核心结论
- 多巴胺激动剂治疗高催乳素血症导致异常瓣膜形态和功能的证据极为有限。
- 除孤立病例报告外,无临床显著瓣膜病变的证据。
- 若无瓣叶厚度、活动受限或回缩等相关病理改变,应避免将瓣膜反流程度变化归因于多巴胺激动剂的不良反应。
研究设计与样本
- 英国超声心动图学会、英国心脏瓣膜学会和内分泌学会联合立场声明。
- 基于现有证据综述,未报告系统检索方法与证据分级。
诊断标准与关键数值
- 开始多巴胺激动剂治疗高催乳素血症前应行标准经胸超声心动图。
- 开始卡麦角林后5年应复查经胸超声心动图,适用于每周总剂量≤2 mg的患者。
- 若5年复查无变化,可继续每5年复查超声心动图。
- 每周总剂量>2 mg的患者推荐每年复查超声心动图。
- 瓣膜病变分级在超声心动图上为半定量,可能因不同机器、超声设置和操作者而异。
临床应用与阅片要点
- 开始多巴胺激动剂治疗前应行标准经胸超声心动图。
- 卡麦角林每周总剂量≤2 mg者用药5年后复查,无变化可每5年复查。
- 卡麦角林每周总剂量>2 mg者推荐每年复查超声心动图。
- 停药决定应仅在经验丰富的超声心动图医师复核系列影像后做出,该医师应擅长分析药物性瓣膜病或类癌心脏病。
- 即使怀疑瓣叶结构和功能形态改变,也应注意超声心动图分级为半定量且受机器、设置和操作者影响。
局限性
- 多巴胺激动剂治疗高催乳素血症导致异常瓣膜形态和功能的证据极为有限。
- 除孤立病例报告外,无临床显著瓣膜病变的证据,而这些病例报告仍存疑问。
- 超声心动图分级为半定量,可能因不同机器、超声设置和操作者而异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
This is a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology on the role of echocardiography in monitoring patients receiving dopamine agonist (DA) therapy for hyperprolactinaemia. Evidence that DA pharmacotherapy causes abnormal valve morphology and dysfunction at doses used in the management of hyperprolactinaemia is extremely limited. Evidence of clinically significant valve pathology is absent, except for isolated case reports around which questions remain. Attributing change in degree of valvar regurgitation, especially in mild and moderate tricuspid regurgitation, to adverse effects of DA in hyperprolactinaemia should be avoided if there are no associated pathological changes in leaflet thickness, restriction or retraction. Note must be taken that even where morphological change in leaflet structure and function may be suspected, grading is semi-quantitative on echocardiography and may vary between different machines, ultrasound settings and operators. Decisions regarding discontinuation of medication should only be made after review of serial imaging by an echocardiographer experienced in analysing drug-induced valvulopathy or carcinoid heart disease. A standard transthoracic echocardiogram should be performed before a patient starts DA therapy for hyperprolactinaemia. Repeat transthoracic echocardiography should then be performed at 5 years after starting cabergoline in patients taking a total weekly dose less than or equal to 2 mg. If there has been no change on the 5-year scan, repeat echocardiography could continue at 5-yearly intervals. If a patient is taking more than a total weekly dose of 2 mg, then annual echocardiography is recommended.
引用
- Steeds R, Stiles C, Sharma V, et al. Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: A joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. Clin Endocrinol (Oxf). 2019. PMID: 30818417. doi:10.1111/cen.13940
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。